Next Phase Newsletter

A USA-based growth equity fund is investing out of its latest fund which closed last year. The firm makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $20-60m per company, and focuses on companies in USA and Canada.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry including products and services. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A hybrid family office can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes opportunistic and strategic investments, and does not have a target minimum or maximum number of investments for any given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience in areas of ophthalmology, dermatology, diabetes, oncology, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are clinical stage, but also capable of supporting companies nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management and product development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare and life sciences focused venture capital firm with USA and China offices has managed $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.

The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.

The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the UK and USA is actively seeking innovative investment opportunities with high potential for growth. With its current fund, the firm invests in digital technologies in the life sciences space. The firm prefers to invest in venture to growth stage companies – in general, companies looking for seed funding will be considered too early-stage for the firm. With this fund, the firm seeks to make 18-20 investments with initial investment sizes in the range of $3-10M. The firm will focus on companies that are based in the UK, USA, and Canada, but may review those from other geographies on a case by case basis.

The firm is most interested in life science companies with a digital component. This includes healthcare IT/digital health, utilization of AI/machine learning for drug discovery, genomics, precision medicine, etc. The firm is open to medical devices or diagnostics that have a digital component. In particular, the firm is most interested in technologies that are dedicated to the treatment of chronic disorders and lead to improved outcomes and lower care costs in hospital systems. The firm will not consider traditional biopharmaceutical modalities.

The firm carefully evaluates investment opportunities based on the quality and experienced of the management team as well as market opportunity. The firm is open to both leading and co-investing, and in the former case will seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the US is currently allocating capital from its third fund, investing between $1-2M in pre-seed and seed-stage companies, targeting approximately 10% as their ownership target. The fund is ~75% deployed and expects to make several more investments over the upcoming quarters. The firm will consider opportunities in the United States and Canada.

Within healthcare and life science, the firm is interested in AI-based, non-consumer healthcare IT products. While the firm is open to all indications, the firm is interested in specialist care (i.e., chronic conditions, telehealth), value-based care enablement, behavioral health, elder care, and clinical trial enablement. The consideration of hardware is limited in the healthcare and life science space.

The firm does not have any requirements of the management team. The firm prefers to lead, but will also co-lead and co-invest. They do not require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital firm with strong China expertise and global capabilities discovers, incubates and grows next-generation life science companies in early and growth stage, worldwide. Their portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs. They operate offices in US and China.

The firm focuses mostly on novel therapeutics, like small molecule, cell therapy, gene therapy, etc, while the firm is also open to enabling technologies and high-end specialty services. The firm is looking to invest from seed, first institutional round, to growth stage.

The firm has no specific requirement for the company & management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm in the US invests in cancer-focused data accessibility and scalability, infrastructure, education and access, and IT and service start-ups as they look to fundamentally change the way cancer care is designed and delivered at scale. Drugs, therapeutics, or medical devices are not of interest. The firm will invest in Seed stage companies that are currently selling in the market. The firm is open to global companies, typically allocating between $250k-1.5M USD. The firm can act as a lead investor and co-investor.

In terms of life science, the firm invests in cancer-focused digital health companies, however, does not invest in drugs, therapeutics, medical devices, and technologies that require FDA approval.

The firm does not have specific management team requirements and does not require to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.